Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer - Episode 4

Clinical Trial Considerations for eBC Treatment Selection

,

Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH], immunohistochemistry [IHC], and circulating DNA [ctDNA]) in defining “high-risk” patients and guiding treatment strategies.

EP. 1: Introduction and HR+/HER2– eBC Overview
EP. 2: Approaches to eBC Diagnosis and Risk Stratification
EP. 3: CDK4/6 Inhibitors Treatment Options in the eBC Setting
Now Viewing
EP. 4: Clinical Trial Considerations for eBC Treatment Selection
EP. 5: Clinical Decision-Making for a Patient With eBC: Scenario and Strategies
EP. 6: Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

Video content above is prompted by the following:

  1. How do you use adjuvant therapy in patients with HR+/HER2–eBC?
    1. How do risk factors impact your adjuvant treatment strategy?
      1. Which risk factors are most influential, and why?
    2. Please discuss some recent adjuvant CDK4/6 inhibitor studies in eBC:
      1. Abemaciclib + endocrine therapy
      2. Ribociclib + nonsteroidal aromatase inhibitor — Final analysis Node-negative (N0) subgroup analysis; NATALEE 4-y
      3. Palbociclib – analysis of the sensitivity to endocrine therapy assay in the PALLAS adjuvant trial of palbociclib Original PALLAS

Related Content:

Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer
Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence
Clinical Decision-Making for a Patient With eBC: Scenario and Strategies
CDK4/6 Inhibitors Treatment Options in the eBC Setting